The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global amniotic membrane market reached a value of US$ 1,290 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 2,220 Million by 2027, exhibiting a CAGR of 9.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The amniotic membrane (AM) forms the innermost layer of the placenta that is mainly composed of an epithelial monolayer, acellular intermediate basement, and an outer mesenchymal cell layer. It surrounds the embryo/fetus and delimits the amniotic cavity, which is filled with amniotic liquid and assists in healing wounds and protecting against infection. It has anti-inflammatories, anti-bacterial, anti-viral, immunological, anti-angiogenic, and proapoptotic properties. As it also aids in preventing the delivery of nutrients and oxygen to cancer cells and consequently interferes with tumor angiogenesis, growth, and metastasis, AM finds wide applications in oncology across the globe.
There is currently a rise in the number of corneal surgeries on account of their ability to reduce pain, restore vision, and improve the appearance of a damaged or diseased cornea. This, along with the increasing geriatric population, represents one of the key factors strengthening the growth of the market. AMs assist in enhancing epithelialization, reinforcing adhesion of basal epithelial cells, maintaining epithelial phenotype, and modulating the proliferation of normal cornea, conjunctivital and limbal fibroblast. As they also prevent apoptosis and inhibit scarring, inflammation, and neovascularization, they are widely employed during corneal transplants around the world. Besides this, AMs are relatively cost-effective compared to xenografts and allografts. Consequently, they find extensive applications in a rising number of cosmetic and reconstructive surgeries worldwide. Furthermore, there is a continuous increase in the funding for research and development (R&D) activities in the field of stem cell and regenerative medicine. This, coupled with a rapid increase in the number of surgeries, is creating a favorable market outlook. Other factors, including growing donations of the placenta and rising demand for tissue-based products for treating surgical wounds, are driving the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global amniotic membrane market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product, application and end user.
Breakup by Product:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Amnio Technology LLC, Amniox Medical Inc. (TissueTech Inc.), Genesis Biologics, Human Regenerative Technologies LLC, Integra LifeSciences Holdings Corporation, Katena Products Inc., MiMedx Group, Next Biosciences, Skye Biologics Holdings LLC, Smith & Nephew plc, Surgenex LLC, Ventris Medical LLC, and Wright Medical Group N.V. (Stryker B.V.).
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Amnio Technology LLC, Amniox Medical Inc. (TissueTech Inc.), Genesis Biologics, Human Regenerative Technologies LLC, Integra LifeSciences Holdings Corporation, Katena Products Inc., MiMedx Group, Next Biosciences, Skye Biologics Holdings LLC, Smith & Nephew plc, Surgenex LLC, Ventris Medical LLC, and Wright Medical Group N.V. (Stryker B.V.)|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at